

Effects of COVID-19 on Primary Percutaneous Coronary Intervention

admissions: is there hidden morbidity?

A. Kalyanasundaram¹, N. Lin Myint¹, H. Asogan¹

¹Royal Papworth Hospital, Cambridge, United Kingdom

INTRODUCTION

The COVID-19 pandemic has had significant consequences on the cardiovascular health of millions worldwide. There has, however, been limited data comparing patients admitted for primary percutaneous coronary intervention (PPCI) during the COVID-era to those admitted in the pre-COVID era, which would be crucial in identifying hidden morbidity. This study considers all PPCI patients admitted to a large cardiothoracic hospital in 2019-2021.

METHODS


The electronic health records of 530 patients (72.6% male, mean age 65.2, 14 COVID positive) admitted to Royal Papworth Hospital (Cambridge, UK) via the PPCI pathway were interrogated for information on demographics, admission COVID status, admission blood test results, 30-day mortality, and 6-month mortality. This group represented every patient admitted via this pathway during the following time frames: April-May 2019 and December 2019-January 2020 (pre-COVID controls), April-May 2020 (“wave 1”), and December 2020-January 2021 (“wave 2”). The pre-COVID time frames were chosen to be exactly one year earlier than wave 1 and 2 to control for seasonal variations. Unpaired two-tailed t-tests were performed using R to compare the characteristics of patients when grouped by wave or COVID status.

RESULTS

Compared to the spring 2019 patients, the group admitted during spring 2020 (wave 1) had a lower proportion of males (64.5% vs 76.6%, $p = 0.045$), a higher proportion of white patients (100% vs 86.3%, $p = 0.00002$), higher admission D-dimer levels (mean 2595 vs 135, $p = 0.013$), and lower troponin levels on admission (mean 4205 vs 6868, $p = 0.04$) and 12 hours post-admission (mean 17948 vs 21995, $p = 0.038$). When compared to winter 2019/20 patients, those admitted during winter 2020/21 (wave 2) had a lower proportion of males (68.9% vs 80.3%, $p = 0.023$) and higher lymphocyte counts (1.81 vs 1.42, $p = 0.043$).

COVID positive patients, compared to COVID negative patients admitted in waves 1 and 2, were younger (mean 56 vs 66, $p = 0.027$), had a lower lymphocyte count (mean 1.22 vs 1.75, $p = 0.025$), and had a lower BNP (mean 638 vs 4923, $p = 0.025$). They also showed a higher rate of 30 day mortality (21.4% vs 6.6%) and 6 month mortality (21.4% vs 8.9%), but neither result was statistically significant, likely owing to the small number of COVID positive patients in the sample.

COVID positive patients admitted during wave 1 were not statistically different on any recorded metric to COVID positive patients admitted during wave 2, though again this may be in part due to the low sample size. Considering all patients in these waves shows that wave 1 patients were more white (100% vs 93.9%, $p = 0.001$), and had a higher BNP (mean 3696 vs 658, $p = 0.03$).



The above graphs illustrate some of our pertinent findings. “Wave 0” represents a summation of the data from Apr-May 2019 and Dec 2019/Jan 2020, i.e. the pre-COVID era. Legends are shown on the right.

CONCLUSIONS

In COVID-time, there was an increase in females undergoing PPCI in both waves, whereas the first wave particularly saw an increase in white patients. Biomarkers such as increased D-dimer, Troponin and BNP were found to be significant in different waves. No major differences were found between two variants of COVID infection.